Human Insulin Receptor Monoclonal Antibody Undergoes High Affinity Binding to Human Brain Capillaries in Vitro and Rapid Transcytosis Through the Blood–Brain Barrier in Vivo in the Primate

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Pharmaceutical Research

• Publication date

  1995-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1023/A:1016244500596PMID 7667183
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Macromolecular permeability across the blood-nerve and blood-brain barriers.

  1994cited by this paper
• Use of neutral avidin improves pharmacokinetics and brain delivery of biotin bound to an avidin-monoclonal antibody conjugate.

  1994cited by this paper
• Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor.

  1994cited by this paper
• Cross-linking of a B25 azidophenylalanine insulin derivative to the carboxyl-terminal region of the alpha-subunit of the insulin receptor. Identification of a new insulin-binding domain in the insulin receptor.

  1994cited by this paper
• Ultrastructural study on the interaction of insulinalbumin-gold complex with mouse brain microvascular endothelial cells

  1994cited by this paper
• Deletion of residues 485-599 from the human insulin receptor abolishes antireceptor antibody binding and influences tyrosine kinase activation.

  1994cited by this paper
• Blood-brain barrier penetration and in vivo activity of an NGF conjugate.

  1993cited by this paper
• Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery.

  1993cited by this paper
• Transport of recombinant CD4 through the rat blood-brain barrier in vivo.

  1992cited by this paper
• Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor.

  1992cited by this paper
• Internalization of the human insulin receptor. The insulin-independent pathway.

  1992cited by this paper
• Peptide drug delivery to the brain

  1991cited by this paper
• Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier.

  1991cited by this paper
• Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo.

  1991cited by this paper
• Identification of epitopes on the human insulin receptor reacting with rabbit polyclonal antisera and mouse monoclonal antibodies.

  1990cited by this paper
• Capillary Depletion Method for Quantification of Blood–Brain Barrier Transport of Circulating Peptides and Plasma Proteins

  1990cited by this paper
• Human brain microvascular DR‐antigen

  1989cited by this paper
• Monoclonal antibodies to the insulin receptor mimic metabolic effects of insulin but do not stimulate receptor autophosphorylation in transfected NIH 3T3 fibroblasts.

  1989cited by this paper
• Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport.

  1987cited by this paper
• Blood-brain barrier transcytosis of insulin in developing rabbits.

  1987cited by this paper
• Receptor‐mediated transcytosis of transferrin across the blood‐brain barrier

  1987cited by this paper
• Human blood-brain barrier transferrin receptor.

  1987cited by this paper
• Monoclonal antibodies reacting with multiple epitopes on the human insulin receptor.

  1986cited by this paper
• Quantitative Autoradiographic Evidence for Insulin Receptors in the Choroid Plexus of the Rat Brain

  1986cited by this paper
• Analysis of lymphopoietic stem cells with a monoclonal antibody to the rat transferrin receptor.

  1985cited by this paper
• Human Blood—Brain Barrier Insulin Receptor

  1985cited by this paper
• Transferrin receptor on endothelium of brain capillaries

  1984cited by this paper
• THE RHESUS MONKEY

  1982cited by this paper
• A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies.

  1981cited by this paper
• Morphology of blood-brain interfaces.

  1977cited by this paper
• Relationship between plasma and cerebrospinal fluid insulin levels of dogs.

  1977cited by this paper
• QUANTITATIVE ANATOMY OF THE CEREBRAL VASCULAR BED WITH ESPECIAL EMPHASIS ON HOMOGENEITY AND INHOMOGENEITY IN SMALL PARTS OF THE GRAY AND WHITE MATTER

  1965cited by this paper

• Selective peptide–guided transcytosis enhances extracellular vesicle–mediated siRNA delivery across the blood–brain barrier

  2025cites this paper
• The legacy of William M. Pardridge (1947–2024) on the science and fields concerned with the physiology of the blood-brain barrier and the transport of drugs to the brain

  2025cites this paper
• Recent advances in potential drug nanocarriers for CNS disorders: a review

  2025cites this paper
• Nanoparticle-based delivery systems for targeted therapy in brain tumors: Progress, challenges and perspectives (Review)

  2025cites this paper
• Translational minimal physiologically based pharmacokinetic model for transferrin receptor-mediated brain delivery of antibodies

  2025cites this paper
• Antibody Engineering for Receptor-Mediated Transcytosis Across the Blood-Brain Barrier.

  2025cites this paper
• Brendo: an open resource for uniquely transcribed genes in brain endothelial cells

  2025cites this paper
• Nose-to-brain delivery of nanotherapeutics: Transport mechanisms and applications.

  2024cites this paper
• Blood–Brain Barrier-Targeting Nanoparticles: Biomaterial Properties and Biomedical Applications in Translational Neuroscience

  2024cites this paper
• Human cell surface-AAV interactomes identify LRP6 as blood-brain barrier transcytosis receptor and immune cytokine IL3 as AAV9 binder

  2024cites this paper
• Advances in Intrathecal Nanoparticle Delivery: Targeting the Blood–Cerebrospinal Fluid Barrier for Enhanced CNS Drug Delivery

  2024cites this paper
• Receptor-mediated transcytosis for brain delivery of therapeutics: receptor classes and criteria

  2024cites this paper
• Insulin receptor at the blood-brain barrier: Transport and signaling.

  2024cites this paper
• Consensus Review on Strategies to Improve Delivery Across the BBB Including Focused Ultrasound.

  2024cites this paper
• Exit pathways of therapeutic antibodies from the brain and retention strategies

  2023cites this paper
• Proteomic alterations in the brain and blood–brain barrier during brain Aβ accumulation in an APP knock-in mouse model of Alzheimer’s disease

  2023cites this paper
• Transferrin Receptor-Targeted Iduronate-2-sulfatase Penetrates the Blood-Retinal Barrier and Improves Retinopathy in Mucopolysaccharidosis II Mice

  2023cites this paper
• Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier

  2023cites this paper
• Treatment of Parkinson’s disease with biologics that penetrate the blood–brain barrier via receptor-mediated transport

  2023cites this paper
• Site-specifically radiolabeled nanobodies for imaging blood-brain barrier penetration and targeting in the brain.

  2023cites this paper
• The use of cyclic peptide antigens to generate LRP8 specific antibodies

  2023cites this paper
• Exosomes-Based Nanomedicine for Neurodegenerative Diseases: Current Insights and Future Challenges

  2023cites this paper
• Ursolic acid nanoparticles for glioblastoma therapy.

  2023cites this paper
• Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrier

  2023cites this paper
• Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans

  2023cites this paper
• Enzyme replacement with transferrin receptor-targeted α-L-iduronidase rescues brain pathology in mucopolysaccharidosis I mice

  2023cites this paper
• Overcoming the blood–brain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches

  2022cites this paper
• A Historical Review of Brain Drug Delivery

  2022cites this paper
• Crossing the Blood-Brain Barrier: Advances in Nanoparticle Technology for Drug Delivery in Neuro-Oncology

  2022cites this paper
• IgG Fusion Proteins for Brain Delivery of Biologics via Blood–Brain Barrier Receptor-Mediated Transport

  2022cites this paper
• Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins.

  2022cites this paper
• Transport of nanomedicines across the blood-brain barrier: Challenges and opportunities for imaging and therapy.

  2022cites this paper
• A review of glucoregulatory hormones potentially applicable to the treatment of Alzheimer’s disease: mechanism and brain delivery

  2022cites this paper
• Strategies for Targeted Delivery of Exosomes to the Brain: Advantages and Challenges

  2022cites this paper
• Targeting insulin‐like growth factor‐1 receptor (IGF1R) for brain delivery of biologics

  2022cites this paper
• The 46.1 Antibody Mediates Neurotensin Uptake into the CNS and the Effects Depend on the Route of Intravenous Administration

  2022cites this paper
• Review of Current Strategies for Delivering Alzheimer's Disease Drugs Across the Blood-Brain Barrier.

  2022cites this paper
• Strategies to overcome/penetrate the BBB for systemic nanoparticle delivery to the brain/brain tumor.

  2022cites this paper
• Current Chemical, Biological, and Physiological Views in the Development of Successful Brain-Targeted Pharmaceutics

  2022cites this paper
• Dual-targeted magnetic mesoporous silica nanoparticles reduce brain amyloid-β burden via depolymerization and intestinal metabolism

  2022cites this paper
• Recent advances in Bio-conjugated nanocarriers for crossing the Blood-Brain Barrier in (pre-)clinical studies with an emphasis on vesicles.

  2022cites this paper
• Targeting Fibronectin to Overcome Remyelination Failure in Multiple Sclerosis: The Need for Brain- and Lesion-Targeted Drug Delivery

  2022cites this paper
• The role of amyloid oligomers in neurodegenerative pathologies.

  2021cites this paper
• Cerebrovascular insulin receptors are defective in Alzheimer’s disease

  2021cites this paper
• Strategies for delivering therapeutics across the blood–brain barrier

  2021cites this paper
• Mathematical Models of Blood-Brain Barrier Transport of Monoclonal Antibodies Targeting the Transferrin Receptor and the Insulin Receptor

  2021cites this paper
• Delivery of Therapeutic Agents to the Central Nervous System and the Promise of Extracellular Vesicles

  2021cites this paper
• Highly Specific Blood-Brain Barrier Transmigrating Single-Domain Antibodies Selected by an In Vivo Phage Display Screening

  2021cites this paper
• Targeting to the CNS: Approach for brain tumor

  2021cites this paper
• IL-6 blockade suppresses the blood-brain barrier disorder, leading to prevention of onset of NMOSD

  2021cites this paper
• Advances in Non-Animal Testing Approaches towards Accelerated Clinical Translation of Novel Nanotheranostic Therapeutics for Central Nervous System Disorders

  2021cites this paper
• Considerations When Developing Blood-Brain Barrier Crossing Drug Delivery Technology.

  2021cites this paper
• Kinetics of Blood–Brain Barrier Transport of Monoclonal Antibodies Targeting the Insulin Receptor and the Transferrin Receptor

  2021influential citation
• Diabetes and the Nervous System

  2021cites this paper
• Brain drug delivery: overcoming the blood-brain barrier to treat tauopathies.

  2020cites this paper
• Delivery of Nanoparticles and Macromolecules across the Blood–Brain Barrier

  2020cites this paper
• Lyoprotectant Optimization for the Freeze-Dry of Receptor-Targeted Trojan Horse Liposomes for Plasmid DNA Delivery.

  2020cites this paper
• Comparison of absolute protein abundances of transporters and receptors among blood-brain barriers at different cerebral regions and blood-spinal cord barrier in human and rat.

  2020cites this paper
• Brain Delivery of Nanomedicines: Trojan Horse Liposomes for Plasmid DNA Gene Therapy of the Brain

  2020influential citation
• Fine-tuning bispecific therapeutics.

  2020cites this paper
• Proteoglycan 4 Reduces Neuroinflammation and Protects the Blood–Brain Barrier after Traumatic Brain Injury

  2020cites this paper
• Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR

  2020cites this paper
• Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain

  2020cites this paper
• Antibody screening using a human iPSC‐based blood‐brain barrier model identifies antibodies that accumulate in the CNS

  2020cites this paper
• Non-Human Primate Blood–Brain Barrier and In Vitro Brain Endothelium: From Transcriptome to the Establishment of a New Model

  2020cites this paper
• Novel cyclic peptides facilitating transcellular blood-brain barrier transport of macromolecules in vitro and in vivo.

  2020cites this paper
• Fine-tuning bispecific therapeutics.

  2020cites this paper
• Treatment of Alzheimer’s Disease and Blood–Brain Barrier Drug Delivery

  2020cites this paper
• Treating brain diseases using systemic parenterally-administered protein therapeutics: Dysfunction of the brain barriers and potential strategies.

  2020cites this paper
• Novel Diagnostic and Therapeutic Immunologic Strategies to Overcome Infectious, Oncologic and Neurodegenerative Disorders

  2020cites this paper
• Efficient engraftment of genetically modified cells is necessary to ameliorate central nervous system involvement of murine model of mucopolysaccharidosis type II by hematopoietic stem cell targeted gene therapy.

  2020cites this paper
• Therapeutic Options for Mucopolysaccharidosis II (Hunter Disease).

  2020cites this paper
• Drug Delivery Strategies to Overcome the Blood-Brain Barrier (BBB).

  2020cites this paper
• Basic principles of brain tumor chemotherapy

  2019cites this paper
• Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease.

  2019cites this paper
• Transnasal delivery of the peptide agonist specific to Neuromedin-U receptor2 to the brain for the treatment of obesity.

  2019cites this paper
• In vitro and in vivo evaluation of a single chain antibody fragment generated in planta with potent rabies neutralisation activity

  2019cites this paper
• Current Approaches and Future Perspectives for Nanobodies in Stroke Diagnostic and Therapy

  2019cites this paper
• Receptor-mediated transportation through BBB

  2019cites this paper
• Review of Current Strategies for Delivering Alzheimer’s Disease Drugs across the Blood-Brain Barrier

  2019influential citation
• Transcytosis - An effective targeting strategy that is complementary to “EPR effect” for pancreatic cancer nano drug delivery

  2019influential citation
• Brain uptake of multivalent and multi-specific DVD-Ig proteins after systemic administration

  2018cites this paper
• Chimeric Small Antibody Fragments as Strategy to Deliver Therapeutic Payloads.

  2018cites this paper
• The Development of a Drug Delivery System Using Brain Endothelial Non-Antibody Binding Domains as Transport Carriers

  2018cites this paper
• A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II

  2018cites this paper
• Facile construction of dual-targeting delivery system by using lipid capped polymer nanoparticles for anti-glioma therapy

  2018cites this paper
• Plasma Pharmacokinetics of Valanafusp Alpha, a Human Insulin Receptor Antibody-Iduronidase Fusion Protein, in Patients with Mucopolysaccharidosis Type I

  2018cites this paper
• The insulin receptor is expressed and functional in cultured blood-brain barrier endothelial cells but does not mediate insulin entry from blood to brain.

  2018cites this paper
• Organ-based drug delivery

  2018cites this paper
• The development of biological therapies for neurological diseases: moving on from previous failures

  2018cites this paper
• Strategies for Enhancing the Permeation of CNS-Active Drugs through the Blood-Brain Barrier: A Review

  2018cites this paper
• Targeted Theranostic Nanoparticles for Brain Tumor Treatment

  2018cites this paper
• Blood-Brain Barrier Transport, Plasma Pharmacokinetics, and Neuropathology Following Chronic Treatment of the Rhesus Monkey with a Brain Penetrating Humanized Monoclonal Antibody Against the Human Transferrin Receptor.

  2018cites this paper
• Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy

  2017cites this paper
• Delivery of Biologics Across the Blood–Brain Barrier with Molecular Trojan Horse Technology

  2017cites this paper
• Non-invasive approaches for drug delivery to the brain based on the receptor mediated transport.

  2017cites this paper
• Can dendrimer based nanoparticles fight neurodegenerative diseases? Current situation versus other established approaches

  2017cites this paper
• Antibody therapies in CNS diseases

  2017influential citation
• Reduction of Cognitive Decline in Patients with or at High Risk for Diabetes

  2017cites this paper
• Insulin and the Brain

  2017cites this paper